{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:43:52Z","timestamp":1794411832896,"version":"4.9.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"SI","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08AR080808"],"award-info":[{"award-number":["K08AR080808"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2TR002245"],"award-info":[{"award-number":["KL2TR002245"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL087738"],"award-info":[{"award-number":["T32HL087738"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Porter Family Fund for Autoimmune Disease Research"},{"name":"VUMC Division of Rheumatology"},{"DOI":"10.13039\/100016220","name":"CTSA","doi-asserted-by":"publisher","award":["UL1 TR002243"],"award-info":[{"award-number":["UL1 TR002243"]}],"id":[{"id":"10.13039\/100016220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Calcineurin inhibitors are commonly used to treat idiopathic inflammatory myopathies related interstitial lung disease (IIM-ILD) in Asia but not in the USA. Here, we evaluate the efficacy of tacrolimus (TAC) as first-line immunosuppressive therapy in a US cohort of IIM-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, single-centre cohort study evaluated the change in absolute forced vital capacity (FVCabs) in IIM-ILD participants after 12\u2009months of treatment with mycophenolate mofetil (MMF), azathioprine (AZA) or TAC. Participants were na\u00efve to immunosuppressive agents other than glucocorticoids and\/or intravenous immunoglobulin. Treatment with MMF, AZA or TAC was at the discretion of their primary clinician. Additional outcomes were transplant-free survival, prednisone use and supplemental oxygen use at 12\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one participants were included in this study. The TAC group was younger and had a shorter disease duration than the MMF\/AZA group. All MDA5 patients were treated with TAC. After 12\u2009months of therapy, the FVCabs was unchanged in the MMF\/AZA group (2.4\u2009l [95% CI 2.0, 3.2\u2009l] vs 2.3\u2009l [95% CI 2.0, 2.8\u2009l]) and improved in TAC group (2.5\u2009l [95% CI 2.0, 3.0\u2009l] vs.1.9 l [95% CI 1.0, 2.6\u2009l]). Transplant-free survival was 100% in both groups. All patients in the MMF\/AZA group remained on supplemental oxygen at 12\u2009months, but 4\/5 patients in the TAC group resolved their oxygen requirement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TAC is effective as a first-line agent in a small, non-randomized US cohort of IIM-ILD enriched for MDA5+ participants. Further work is needed to investigate the relative efficacy of calcineurin inhibitors compared with MMF\/AZA in the US population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf063","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T15:33:51Z","timestamp":1738251231000},"page":"SI179-SI183","source":"Crossref","is-referenced-by-count":2,"title":["Tacrolimus as first-line therapy in a US cohort of idiopathic inflammatory myopathies related interstitial lung disease"],"prefix":"10.1093","volume":"64","author":[{"given":"Kamaree J R","family":"Harris","sequence":"first","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Centre , Nashville, TN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica A","family":"Ludtke","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Centre , Nashville, TN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaire","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Centre , Nashville, TN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3215-8649","authenticated-orcid":false,"given":"Natalie N","family":"McCall","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Centre , Nashville, TN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-6386","authenticated-orcid":false,"given":"Justin C","family":"Hewlett","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Centre , Nashville, TN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6584-1578","authenticated-orcid":false,"given":"Erin M","family":"Wilfong","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Centre , Nashville, TN,","place":["USA"]},{"name":"Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Centre , Nashville, TN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"2025121017321326900_keaf063-B1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung"},{"key":"2025121017321326900_keaf063-B2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025121017321326900_keaf063-B3","doi-asserted-by":"crossref","first-page":"e0133702","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS One"},{"key":"2025121017321326900_keaf063-B4","doi-asserted-by":"crossref","first-page":"820163","DOI":"10.3389\/fimmu.2021.820163","article-title":"Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review","volume":"12","author":"He","year":"2022","journal-title":"Front Immunol"},{"key":"2025121017321326900_keaf063-B5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","article-title":"The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis","volume":"54","author":"Kurita","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2025121017321326900_keaf063-B6","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/art.21240","article-title":"Treatment of antisynthetase-associated interstitial lung disease with tacrolimus","volume":"52","author":"Wilkes","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025121017321326900_keaf063-B7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10067-014-2803-z","article-title":"Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2025121017321326900_keaf063-B8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis\u2013associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2025121017321326900_keaf063-B9","doi-asserted-by":"crossref","first-page":"152474","DOI":"10.1016\/j.semarthrit.2024.152474","article-title":"Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: a retrospective cohort study","volume":"68","author":"Shan","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025121017321326900_keaf063-B10","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025121017321326900_keaf063-B11","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121017321326900_keaf063-B12","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/resp.14579","article-title":"Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis","volume":"28","author":"Maher","year":"2023","journal-title":"Respirology"},{"key":"2025121017321326900_keaf063-B13","doi-asserted-by":"crossref","first-page":"101073","DOI":"10.1016\/j.eclinm.2021.101073","article-title":"Prognostic implications of differences in forced vital capacity in black and white US adults: findings from NHANES III with long-term mortality follow-up","volume":"39","author":"Gaffney","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025121017321326900_keaf063-B14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.chest.2023.03.026","article-title":"Effect of race and ethnicity on pulmonary function testing interpretation: an American College of Chest Physicians (CHEST), American Association for Respiratory Care (AARC), American Thoracic Society (ATS), and Canadian Thoracic Society (CTS) evidence review and research statement","volume":"164","author":"Marciniuk","year":"2023","journal-title":"Chest"},{"key":"2025121017321326900_keaf063-B15","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2025121017321326900_keaf063-B16","first-page":"373","article-title":"A systematic review and metaanalysis of predictors of mortality in idiopathic inflammatory myopathy\u2013associated interstitial lung disease","volume":"50","author":"Hannah","year":"2023","journal-title":"J Rheumatol"},{"key":"2025121017321326900_keaf063-B17","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","article-title":"Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients","volume":"57","author":"Sato","year":"2018","journal-title":"Rheumatology"},{"key":"2025121017321326900_keaf063-B18","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00296-016-3571-7","article-title":"Outcome and prognostic factors in a French cohort of patients with myositis-associated interstitial lung disease","volume":"36","author":"Obert","year":"2016","journal-title":"Rheumatol Int"},{"key":"2025121017321326900_keaf063-B19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12890-019-0943-2","article-title":"Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study","volume":"19","author":"Chan","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2025121017321326900_keaf063-B20","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1093\/rheumatology\/keab928","article-title":"Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"61","author":"Wang","year":"2022","journal-title":"Rheumatology"},{"key":"2025121017321326900_keaf063-B21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","article-title":"Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease","volume":"154","author":"Huapaya","year":"2019","journal-title":"Respir Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf063\/61740734\/keaf063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/SI\/SI179\/61740734\/keaf063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/SI\/SI179\/61740734\/keaf063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:32:22Z","timestamp":1765405942000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/SI\/SI179\/7997279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":21,"journal-issue":{"issue":"SI","published-online":{"date-parts":[[2025,2,3]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf063","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,2,3]]}}}